These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36835157)

  • 1. ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid.
    Meligova AK; Siakouli D; Stasinopoulou S; Xenopoulou DS; Zoumpouli M; Ganou V; Gkotsi EF; Chatziioannou A; Papadodima O; Pilalis E; Alexis MN; Mitsiou DJ
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptors β1 and β2 are associated with distinct responses of estrogen receptor α-positive breast carcinoma to adjuvant endocrine therapy.
    Dhimolea E; Tiniakos DG; Chantzi ΝΙ; Goutas N; Vassilaros SD; Mitsiou DJ; Alexis ΜN
    Cancer Lett; 2015 Mar; 358(1):37-42. PubMed ID: 25524554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
    Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
    J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
    Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
    BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.
    Vinayagam R; Sibson DR; Holcombe C; Aachi V; Davies MP
    BMC Cancer; 2007 Jul; 7():131. PubMed ID: 17640362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
    Chan KKL; Siu MKY; Jiang YX; Wang JJ; Wang Y; Leung THY; Liu SS; Cheung ANY; Ngan HYS
    BMC Cancer; 2017 Aug; 17(1):606. PubMed ID: 28859612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer.
    Davies MP; O'Neill PA; Innes H; Sibson DR; Prime W; Holcombe C; Foster CS
    J Mol Endocrinol; 2004 Dec; 33(3):773-82. PubMed ID: 15591034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
    Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
    J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
    Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
    Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of estrogen receptor β2 in breast cancer.
    Baek JM; Chae BJ; Song BJ; Jung SS
    Int J Surg; 2015 Feb; 14():17-22. PubMed ID: 25450264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers.
    O'Neill PA; Davies MP; Shaaban AM; Innes H; Torevell A; Sibson DR; Foster CS
    Br J Cancer; 2004 Nov; 91(9):1694-702. PubMed ID: 15477865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.
    Yan M; Rayoo M; Takano EA; ; Fox SB
    Breast Cancer Res Treat; 2011 Apr; 126(2):395-405. PubMed ID: 20490651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments.
    Ao A; Morrison BJ; Wang H; López JA; Reynolds BA; Lu J
    PLoS One; 2011 Apr; 6(4):e18810. PubMed ID: 21533195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
    Speirs V; Viale G; Mousa K; Palmieri C; Reed SN; Nicholas H; Cheang M; Jassem J; Lønning PE; Kalaitzaki E; van de Velde CJH; Rasmussen BB; Verhoeven DM; Shaaban AM; Bartlett JMS; Bliss JM; Coombes RC;
    Ann Oncol; 2015 Sep; 26(9):1890-1897. PubMed ID: 26002610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
    Long X; Fan M; Nephew KP
    Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning, characterisation, and expression of three oestrogen receptors (ERalpha, ERbeta1 and ERbeta2) in the European sea bass, Dicentrarchus labrax.
    Halm S; Martínez-Rodríguez G; Rodríguez L; Prat F; Mylonas CC; Carrillo M; Zanuy S
    Mol Cell Endocrinol; 2004 Aug; 223(1-2):63-75. PubMed ID: 15279912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
    Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
    Margueron R; Duong V; Bonnet S; Escande A; Vignon F; Balaguer P; Cavaillès V
    J Mol Endocrinol; 2004 Apr; 32(2):583-94. PubMed ID: 15072561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.